Schedule 13D ownership disclosure

Allogene Therapeutics Inc

Security class unavailable · CUSIP: 019770106

Event date: 2020-06-25

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
19,716,306
Percent of class
14.2000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001387131-20-006309
Form type
SC 13D/A
Filer
Allogene Therapeutics, Inc.
CIK
CIK 1737287
Filed
Jul 10, 2020
Reporting period
Jun 25, 2020
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub